MedTrace Logo

A Study of GC101 TIL in Advanced Melanoma (BZ)

NCT06120712 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-12-23

No results posted yet for this study

Summary

20 participants are expected to be enrolled for the Phase Ib clinical trial，this trail is expected to be finished in 20 months.

Conditions

  • Tumor Infiltrating Lymphocytes
  • Safety
  • Melanoma
  • Efficacy
  • Adverse Drug Event

Interventions

BIOLOGICAL

GC101 TIL

Patients with advanced, recurrent or metastatic melanoma (excluding uveal melanoma) who have failed standard treatment such as PD-1 antibodies (if BRAF mutation is present, BRAF and MEK inhibitors have failed) and are ineligible for resection."

Sponsors & Collaborators

  • Shanghai Juncell Therapeutics

    lead INDUSTRY

Principal Investigators

  • Jun Guo · Peking University Cancer Hospital & Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-08
Primary Completion
2024-11-12
Completion
2025-11-12

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06120712 on ClinicalTrials.gov